For years, biotech investors have been obsessed with cancer, obesity drugs and gene editing.
Meanwhile, one of medicine’s oldest enemies has been quietly getting stronger: Bacteria.
The ones behind stomach ulcers, infected medical implants, bloodstream infections and hospital-acquired diseases.
The problem is that many of these bacteria are increasingly learning how to survive existing antibiotics.
Doctors call it antimicrobial resistance. In simple terms, the drugs that used to work are slowly losing their punch.
The World Health Organization has repeatedly warned that antimicrobial resistance is becoming one of the biggest threats to global health.
That backdrop helps explain why investors suddenly piled into TenNor Therapeutics (HKEX: 6872).
When the Suzhou-based biotech debuted on the Hong Kong Stock Exchange last week, the market response was explosive.
TenNor priced its IPO at HK$75.70 per share, raising roughly HK$598 million in net proceeds. Within days, the stock had surged as much as 180%, giving the company a market value of around HK$10.9 billion.
For a company that is still pre-revenue, that kind of enthusiasm tells you investors believe something significant may be approaching.
The problem nobody solved properly
Modern medicine depends on antibiotics far more than most people realise.
Without them, many surgeries become riskier. Cancer treatments become more dangerous. Joint replacements, heart procedures and even routine hospital care become harder.
The challenge is that bacteria evolve.
Many older antibiotics were designed to hit a single bacterial target. Over time, bacteria developed ways around those attacks.
Think of it like a burglar learning how to bypass a single lock. The pharmaceutical industry has struggled for decades to stay ahead of that adaptation cycle.
That is where TenNor believes it has an advantage.
Rather than relying on traditional single-target approaches, the company has spent years developing what it calls a multi-target conjugate molecule platform.
It sounds highly technical, but the concept is actually fairly straightforward.
Instead of attacking bacteria through one pathway, the company designs molecules that can strike multiple bacterial functions at the same time.
Imagine trying to shut down a criminal operation.
Closing one door may slow it down. Locking several doors simultaneously makes escape much harder. That is essentially the philosophy behind TenNor’s technology.
The company believes this approach could help overcome two of the biggest problems in infectious disease treatment: antimicrobial resistance and antimicrobial tolerance.
Resistance occurs when bacteria learn how to defeat a drug.
Tolerance occurs when bacteria effectively go into survival mode, allowing them to endure treatment without necessarily becoming genetically resistant.
Both are major challenges for doctors worldwide.
The stomach bug opportunity
The company’s most advanced asset is rifasutenizol, also known as TNP-2198.
This is the drug that investors are watching most closely.
TenNor submitted a New Drug Application to China’s National Medical Products Administration in August 2025 for the treatment of Helicobacter pylori, better known as H. pylori.
Many people have never heard of H. pylori, despite it being one of the most common bacterial infections globally.
The bacterium lives in the stomach lining and is a major cause of gastric ulcers. More importantly, long-term infection is also associated with stomach cancer.
Hundreds of millions of people are believed to carry H. pylori worldwide.
Current treatments generally involve combinations of antibiotics and acid-reducing drugs. The problem is that resistance rates continue to rise, reducing effectiveness in many patients.
TenNor’s rifasutenizol is designed to address that challenge through a differentiated mechanism.
The company’s Phase III study met its primary endpoint, a critical milestone that helped push the drug toward regulatory review.
If approved, rifasutenizol could become one of the first targeted combination regimens specifically designed to tackle H. pylori with a novel molecular approach.
Beyond stomach infections
What makes TenNor particularly interesting is that it is not a one-drug story.
The company has built a pipeline of seven programs, with several targeting difficult bacterial infections that hospitals continue to struggle with.
Its second core asset, rifaquizinone, also known as TNP-2092, is aimed at implant-associated infections.
These are among the most frustrating infections in medicine.
When bacteria attach themselves to medical devices such as artificial joints, catheters or heart pumps, they often form what are known as biofilms.
A biofilm is essentially a protective bacterial fortress. Once established, it becomes extremely difficult for antibiotics to penetrate.
Doctors sometimes have no choice but to remove the implanted device entirely.
TenNor’s TNP-2092 is designed as a triple-targeting antibacterial therapy intended to attack these infections more effectively.
The program has already received multiple designations from the U.S. Food and Drug Administration, including Qualified Infectious Disease Product status and Orphan Drug designation for certain indications.
Those designations can provide regulatory advantages, development incentives and potentially faster review pathways.
For a biotechnology company, that can significantly improve the commercial equation.
Why investors are paying attention
TenNor is not yet profitable.
The company has accumulated losses while advancing its pipeline through clinical development.
That is normal for emerging biotechnology businesses.
What investors appear to be betting on is the possibility that TenNor is approaching the transition point that changes everything.
The company is no longer purely a research story. It is becoming a commercialisation story.
It now has late-stage clinical data, regulatory submissions, manufacturing licences and commercial partnerships already taking shape.
And if its lead programs successfully cross the regulatory finish line, the company may find itself fighting a battle most investors had almost forgotten mattered.
Now read: Hot Take: InventisBio could be China’s next big oncology winner
Follow us on X for more under-the-radar tech and biotech plays from Asia: https://x.com/ChairmanAsiaX
